GSK
GSK
798 hedge funds and large institutions have $12.7B invested in GSK in 2021 Q2 according to their latest regulatory filings, with 95 funds opening new positions, 275 increasing their positions, 260 reducing their positions, and 64 closing their positions.
48% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 64
40% more funds holding in top 10
Funds holding in top 10: 10 → 14 (+4)
39% more call options, than puts
Call options by funds: $241M | Put options by funds: $173M
12% more capital invested
Capital invested by funds: $11.3B → $12.7B (+$1.41B)
3% more funds holding
Funds holding: 774 → 798 (+24)
6% more repeat investments, than reductions
Existing positions increased: 275 | Existing positions reduced: 260
0.04% more ownership
Funds ownership: 5.04% → 5.08% (+0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$231M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$107M |
| 3 |
CA
Capitolis Advisors
New York
|
+$58.6M |
| 4 |
Barclays
London,
United Kingdom
|
+$44.5M |
| 5 |
Goldman Sachs
New York
|
+$35.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$296M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$74.2M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$54.6M |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
-$37.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$37M |
GSK Hedge Fund Activity: Q2 2021 in Review
798 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q2 2021, worth a combined $12.7B — up 12% from $11.3B a quarter earlier.
Buyers outnumbered sellers: 95 funds opened new GSK positions and 64 closed out — a net gain of 31 holders — while 275 added to existing stakes and 260 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $231M. The largest seller was Royal Bank of Canada, cutting an estimated $296M.
- 798 institutional investors held GSK (GSK) as of Q2 2021, up from 774 in Q1 2021.
- Funds reported $12.7B of GSK stock for Q2 2021, up 12% quarter-over-quarter.
- 95 funds opened new GSK positions in Q2 2021 and 64 closed out, a net change of +31 holders.
- The largest GSK buyer in Q2 2021 was BNP Paribas Financial Markets, an estimated $231M added.
- The largest GSK seller in Q2 2021 was Royal Bank of Canada, an estimated $296M sold.
Based on aggregated 13F filings for Q2 2021.